SCHEMBL4748693

SCHEMBL4748693

C[C@]12CN(C(=O)OCc3ccccc3)C[C@H]1C1(CC1)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTR2C P28335 2/20 0.46
CYP2C19 P33261 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HTT P42858 1/20 0.42
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
KDM1A O60341 1/20 0.41
ENPP2 Q13822 1/20 0.39
ATXN2 Q99700 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
DRD1 P21728 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4748671 0.84 SMN1; SMN2 (0.45) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL14140021 0.82 RORC (0.48) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL14405523 0.81 SMN1; SMN2 (0.43) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL4795020 0.80 SMN1; SMN2 (0.42) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL4749403 0.79 SMN1; SMN2 (0.50) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL31634674 0.78 SMN1; SMN2 (0.52) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL22605195 0.78 SMN1; SMN2 (0.52) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL20520922 0.77 SMN1; SMN2 (0.48) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL30210344 0.77 SMN1; SMN2 (0.48) RORCSMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL34474162 0.77 SMN1; SMN2 (0.48) RORCSMN1; SMN2NPC1RAB9AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-22 US disclosed
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US disclosed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 RORC 519/4885SMN1; SMN2 3878/4885NPC1 4439/4885
US-20140142096-A1 Fused Substituted Aminopyrrolidine Derivative NQO2, QDPR, IL4I1 RORC 519/4885SMN1; SMN2 3878/4885NPC1 4439/4885
US-20130029977-A9 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 RORC 519/4885SMN1; SMN2 3878/4885NPC1 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.